Pfizer and Astellas have, this morning, announced that the addition of enzalutamide to standard androgen deprivation (ADT) has led to improved outcomes in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, ARCHES, deprivation, enzalutamide, hormone, outcome, sensitive, standard, trial | 2 Comments »
A group of Spanish clinical researchers have reported recent data from a small study designed to address an unanswered question about the recovery of (relatively) normal hormonal function after completion of androgen deprivation therapy (ADT). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, deprivation, function, hormone, long-term | 4 Comments »
It will come as no great surprise to most readers of this blog that androgen deprivation therapy (ADT) used in the treatment of men with progressive forms of prostate cancer comes with a significant risk for depression (as well as other effects on cognitive function). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, depression, deprivation, hormone, Management | 1 Comment »
As our regular readers will be well aware, the topic of risk for cardiovascular disease among prostate cancer patients being treated with any form of androgen deprivation therapy (ADT, also known as “hormone” therapy) comes up on a regular basis. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: ADT, androgen, cardiovascular, deprivation, hormone, risk | 3 Comments »
Over the years there have been multiple debates about whether different types of androgen deprivation therapy (ADT) really do or don’t extend the survival of men with advanced prostate cancer of differing types and whether the degree to which ADT initially suppresses serum testosterone levels affects that survival. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, deprivation, hormone, serum, testosterone | 48 Comments »
In another paper just published on-line in JAMA Internal Medicine this week, the authors have provided additional data indicating — once again — the lack of any value of primary androgen deprivation therapy (ADT) in the management of early-stage, localized prostate cancer among older patients. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, delayed, deprivation, early, hormone, primary, therapy | Leave a comment »
An article just published in the journal Cancer has reported an association between the use of androgen deprivation therapy (ADT) and risk for blood clots among men being treated for prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, blood clot, hormone, risk, thromboembolism | 10 Comments »
A new article in Lancet Oncology has reported that a mere 6 months of neoadjuvant hormone therapy, when combined with radiation therapy, cuts the risk of dying from locally advanced prostate cancer by 50 percent compared to radiation alone at 10 years of follow-up. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, hormone, neoadjuvant, outcome, radiation, survival | 12 Comments »
There has long been discussion about the appropriate and inappropriate uses of androgen deprivation therapy (ADT) in the management of progressive prostate cancer. The “New” Prostate Cancer InfoLink has regularly commented on the inherent dangers of using ADT to “manage PSA levels” as opposed to managing a patient’s actual clinical condition. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, hormone, therapy, timing | 9 Comments »
Long-term follow-up data have just been published from two studies designed to provide preliminary information on the potential use of very aggressive forms of treatment in men with high-risk categories of prostate cancer. … READ MORE …
Filed under: Management, Treatment | Tagged: aggressive, androgen deprivation, docetaxel, hormone, paclitaxel, radiation, taxane, therapy | 7 Comments »
A new study has shown that the generically available, oral, bisphosphonate risedronate (Actonel) can prevent bone loss and related effects in patients receiving hormonal therapy for prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: bisphosphonate, bone, hormone, loss, risedronate, therapy, turnover | Leave a comment »
Historically there have been few really compelling data available to support the use of an additional or alternative antiandrogen as a second-line agent to extend either progression-free or overall survival of castration-resistant prostate cancer (CRPC) patients who progress after first-line hormone therapy (whether they have been treated by orchiectomy or medical castration with an LHRH agonist). … READ MORE …
Filed under: Management, Treatment | Tagged: antiandrogen, bicalutamide, high-dose, hormone, second-line, therapy | Leave a comment »
A new — but very small and short-term study — has attempted to assess the baseline prevalence of cognitive impairment in older men treated with androgen deprivation therapy (ADT) and changes in cognitive performance over time. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, cognitive, function, hormone, performance, therapy | 1 Comment »
There is an increasing belief among at least some opinion-leaders in the prostate cancer treatment community that androgen deprivation therapy has been and still is being significantly overused. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, hormone, therapy | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 